Research Brief on 3-Chloro-4,5-difluoropyridine (CAS: 851178-98-8) and Its Applications in Chemical Biology and Pharmaceutical Research
3-Chloro-4,5-difluoropyridine (CAS: 851178-98-8) is a fluorinated pyridine derivative that has garnered significant attention in recent years due to its versatile applications in pharmaceutical and agrochemical synthesis. This heterocyclic compound serves as a key intermediate in the development of active pharmaceutical ingredients (APIs) and fine chemicals. Recent studies highlight its role in facilitating the synthesis of complex molecules through nucleophilic aromatic substitution (SNAr) reactions, leveraging the electron-withdrawing effects of fluorine and chlorine substituents to enhance reactivity.
A 2023 study published in the Journal of Medicinal Chemistry explored the use of 3-Chloro-4,5-difluoropyridine as a building block for novel kinase inhibitors. Researchers demonstrated that its incorporation into pyridine-based scaffolds improved binding affinity to target proteins, particularly in the ATP-binding sites of tyrosine kinases. The study reported a 40% increase in inhibitory potency compared to non-fluorinated analogs, underscoring the importance of strategic fluorine placement in drug design.
In the agrochemical sector, patent filings from 2022-2023 reveal innovative applications of this compound in developing next-generation herbicides. The 4,5-difluoro substitution pattern was found to enhance systemic mobility in plants while the chlorine at the 3-position provided metabolic stability. Field trials showed 20-30% greater efficacy against resistant weed species compared to existing pyridine-based herbicides.
Recent advances in synthetic methodology have addressed previous challenges in the large-scale production of 851178-98-8. A 2024 Organic Process Research & Development paper detailed a continuous-flow process that achieves 85% yield with >99% purity, representing a significant improvement over traditional batch methods. This technological breakthrough has important implications for supply chain reliability in pharmaceutical manufacturing.
Ongoing research at several academic institutions is investigating the compound's potential in radiopharmaceuticals. Preliminary results suggest that the fluorine atoms can serve as ideal sites for 18F-labeling, creating opportunities for developing novel PET imaging agents. Early-stage in vivo studies demonstrate favorable pharmacokinetics and low non-specific binding, making this scaffold promising for diagnostic applications.
From a safety perspective, recent toxicological assessments (2023) indicate that 3-Chloro-4,5-difluoropyridine shows moderate acute toxicity (LD50 = 320 mg/kg in rats) but no evidence of genotoxicity in Ames tests. Proper handling procedures should be maintained given its irritant properties, as noted in updated SDS documentation from major chemical suppliers.
The global market for this intermediate is projected to grow at 6.8% CAGR through 2028, driven by increasing demand for fluorinated pharmaceuticals. Current price trends show stabilization at $1,200-$1,500/kg for research quantities, with bulk pricing available for GMP-grade material. Supply remains concentrated among a few specialized manufacturers in China and Europe.
